Clinical Trial: Study of Enfuvirtide in HIV-Positive Subjects

This study has been completed.

Sponsors and Collaborators: Trimeris
Hoffmann-La Roche
Information provided by: Trimeris

Purpose

A total of 26 patients will be admitted to the clinic where they will be dosed with each injection device. There will be a 7-day washout between doses and a 7-10 day follow-up period.

Condition Treatment or Intervention Phase
HIV Infections
AIDS
 Drug: Fuzeon
Phase I

MedlinePlus related topics:  AIDS

Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Dose Comparison, Crossover Assignment, Pharmacokinetics/Dynamics Study

Official Title: An Open-label, Randomized, Cross-over Study in HIV-Positive Subjects to Determine and Compare the Single-dose Pharmacokinetics of Enfuvirtide after a Single 90 mg SC Administration

Eligibility

Ages Eligible for Study:  18 Years   -   64 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

    Exclusion Criteria:


    Location Information


    Florida
          SFBC, Miami,  Florida,  33181,  United States

    More Information

    Study ID Numbers:  T20-405
    Record last reviewed:  April 2004
    Last Updated:  October 13, 2004
    Record first received:  July 8, 2004
    ClinicalTrials.gov Identifier:  NCT00086710
    Health Authority: United States: Food and Drug Administration
    ClinicalTrials.gov processed this record on 2005-04-08


    Source: ClinicalTrials.gov
    Cache Date: April 9, 2005

    Resources